BA
RXRX icon

Bridgewater Associates’s Recursion Pharmaceuticals RXRX Stock Holding History

Bridgewater Associates’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
+37,667
New +$125K ﹤0.01% 995

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bridgewater Associates's RXRX Position: Q2 2026 in Review

Bridgewater Associates opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 37,667 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #995 among its holdings.

342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Bridgewater Associates held 37,667 shares of Recursion Pharmaceuticals worth $138K as of Q2 2026.
  • Recursion Pharmaceuticals was a new Bridgewater Associates position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Bridgewater Associates's portfolio in Q2 2026, its #995 holding.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.